朱绿玉,韩志伟,薛林,王春燕,李昱熙,易铁慈,张岩,龚艳君,范芳芳,李建平,霍勇

• 1:北京大学第一医院心内科

摘要(Abstract)：

目的经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)围手术期心肌梗死的发生与术前抗栓治疗关系密切,但至今还没有理想的临床指标评价PCI术前的抗栓治疗效果。Sonoclot是一种以血液黏度为基础体外实时监测凝血功能和血小板功能的方法。本研究拟入选急性冠状动脉综合征(ACS)患者,PCI术前进行Sonoclot检测,评价Sonoclot指标与PCI围手术期心肌梗死发生的相关性,寻找可以评价PCI术前抗栓疗效的指标。方法前瞻性连续入选2009年9月至2010年7月收住在北京大学第一医院心内科、临床诊断为非ST段抬高急性冠脉综合征并接受冠状动脉造影及介入治疗的患者。收集一般临床资料,根据PCI术后心肌标记物升高至正常值上限3倍以上与否判断患者是否发生围手术期心肌梗死,使用Sonoclot凝血及血小板功能分析仪(Sonoclot coagulation&platelet function analyzer,SCA,SIENCO,Inc,USA)完成ACT(activited clotting time,激活凝血时间)、CR(clot rate,凝血速率)、PF(platelet function,血小板功能)等指标的检测。结果共入组患者246例,其中,男性163例(66.3%),女性83例(33.7%),年龄分布于27～87岁之间,平均(64.3±11.2)岁。其中119例(48.4%)发生围手术期心肌梗死,与未发生者相比,性别、术中肝素用量、多支血管病变比例差异具有统计学意义。另外,经Sonoclot测得的肝素化前CR(gbCR)在两组间差异存在统计学意义(21.32比19.83,t=-2.000,P<0.05)。进一步按照gbCR的75%分位数(gbCR=24)将患者分为两组,结果显示,gbCR高于四分位数患者围手术期心梗风险明显增加(OR:1.94,95%CI:1.05～3.59,P=0.04)。对性别、年龄、BMI、多支血管病变、肝素用量、PT值、FIB值、gbCR等多个因素进行Logistic回归分析显示,gbCR是PCI围手术期心梗的独立预测因素(OR=2.36,95%CI:1.05～5.28)。结论肝素化前CR值与PCI围手术期心肌梗死具有显著相关性,提示对该指标的监测可能会预测PCI围术期心肌梗死的发生风险。

关键词(KeyWords)： 血管成形术,经腔,经皮冠状动脉;手术期间;心肌梗死

Abstract:

Keywords:

基金项目(Foundation): 首都发展基金(2007-3007)

作者(Author): 朱绿玉,韩志伟,薛林,王春燕,李昱熙,易铁慈,张岩,龚艳君,范芳芳,李建平,霍勇

参考文献(References)：

• [1]Levine GN,Bates ER,Blankenship JC,et al.2011ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention:executive summary:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.Circulation,2011,124:2574-2609.
• [2]Akkerhuis KM,Alexander JH,Tardiff BE,et al.Minor myocardial damage and prognosis:are spontaneous and percutaneous coronary intervention-related events different?Circulation,2002,105:554-556.
• [3]Motovska Z,Kala P.Benefits and risks of clopidogrel use in patients with coronary artery disease:Evidence from randomized studies and registries.Clin Ther,2008,30:2191-2202.
• [4]Steinhubl SR,Berger PB,Mann JT3rd,et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial.JAMA,2002,288:2411-2420.
• [5]Patti G,Colonna G,Pasceri V,et al.Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention:results from the ARMYDA-2(Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty)study.Circulation,2005,111:2099-2106.
• [6]Marmur JD,Poludasu S,Feit A,et al.Activated clotting time(ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.J Invasive Cardiol,2008,20:323-327.
• [7]Hett DA,Walker D,Pilkington SN,et al.Sonoclot analysis.Br J Anaesth,1995,75:771-776.
• [8]Mann KG.Membrane-bound enzyme complexes in blood coagulation.Prog Hemost Thromb,1984,7:1-23.
• [9]Tuman KJ,Spiess BD,McCarthy RJ,et al.Comparison of viscoelastic measures of coagulation after cardiopulmonary bypass.Anesth Analg,1989,69:69-75.
• [10]Pleym H,Wahba A,Bjella L,et al.Sonoclot analysis in coronary artery surgery:a comparison between patients with unstable coronary artery disease treated with enoxaparin before surgery and patients with stable coronary artery disease not treated with enoxaparin.J Cardiothorac Vasc Anesth,2008,22:670-674.
• [11]Bhatt DL,Topol EJ.Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in2005?Periprocedural cardiac enzyme elevation predicts adverse outcomes.Circulation,2005,112:906-915.